International Journal of Clinical Pharmacy

, Volume 38, Issue 4, pp 780–783 | Cite as

The effect of intratympanic gentamicin for treatment of Ménière’s disease on lower frequency hearing

  • Gerben SamEmail author
  • Dick Wong Chung
  • Ruud van der Hoeven
  • Sjoerd Verweij
  • Matthijs Becker
Short Research Report


Background The intratympanic application of the ototoxic aminoglycoside gentamicin has shown promising results as an ablative treatment for vertigo associated with Ménière’s disease. Objective To evaluate the efficacy and safety of intratympanic gentamicin and to specifically analyse the effect of this treatment on high and low hearing frequencies in patients with unilateral definite Ménière’s disease. Method Subjects were treated with intratympanic gentamicin and were evaluated on vertigo, tinnitus, mean pure tone audiometry threshold and speech discrimination score. Subjects were followed for evaluation for up to 2 years after treatment. Results The number of vertigo spells per month decreased and subjects experienced less tinnitus. During follow up there was an increase of hearing loss in the low (0.25-, 0.5-, 1-kHz) frequency range (13.3 dB; p = 0.03). There was no significant increase of hearing loss in the high (2-, 4-, 8-kHz) frequency range. A clinically significant change in speech discrimination score was found in 50 % of the subjects. Conclusion Our results indicate that intratympanic gentamicin especially affects the mean pure tone audiometry threshold in the low frequency range, which may have clinical implications. Though many of our results are (statistically) substantial the study was limited by the small cohort size.


Gentamycin Hearing loss Intratympanic administration Ménière’s disease Vertigo 



We would like to express our gratitude to Tjeerd van der Ploeg for his support for the statistical analysis. We also thank the patients and the hospital for their cooperation in this study.


This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

Conflicts of interest

None. (The authors declare that they have no affiliations with or involvement in any organization or entity with any financial interest in the subject matter or materials discussed in this manuscript.)


  1. 1.
    Furukawa M, Kitahara T, Horii A, Uno A, Imai T, Ohta Y, et al. Psychological condition in patients with intractable Meniere’s disease. Acta Otolaryngol. 2013;133(6):584–9.CrossRefPubMedGoogle Scholar
  2. 2.
    Nabi S, Parnes LS. Bilateral Meniere’s disease. CurrOpinOtolaryngol Head Neck Surg. 2009;17(5):356–62.Google Scholar
  3. 3.
    Postema RJ, Kingma CM, Wit HP, Alberts FW, van der Laan BF. Intratympanic gentamicin therapy for control of vertigo in unilateral Menire’s disease: a prospective, double-blind, randomized, placebo-controlled trial. Acta Otolaryngol. 2008;128(8):876–80.CrossRefPubMedGoogle Scholar
  4. 4.
    Pullens B, van Benthem PP. Intratympanic gentamicin for Ménière’s disease or syndrome. Cochrane Database Syst Rev. 2011;3:CD008234.PubMedGoogle Scholar
  5. 5.
    American Academy of Otolaryngology-Head and Neck Foundation, Inc. Committee on Hearing and Equilibrium guidelines for the diagnosis and evaluation of therapy in Menière’s disease. Otolaryngol Head Neck Surg. 1995;113(3):181–5.Google Scholar
  6. 6.
    Stokroos R, Kingma H. Selective vestibular ablation by intratympanic gentamicin in patients with unilateral active Meniere’s disease: a prospective, double-blind, placebo-controlled, randomized clinical trial. Acta Otolaryngol. 2004;124(2):172–5.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing 2016

Authors and Affiliations

  • Gerben Sam
    • 1
    Email author
  • Dick Wong Chung
    • 2
  • Ruud van der Hoeven
    • 1
  • Sjoerd Verweij
    • 1
  • Matthijs Becker
    • 1
  1. 1.Department of PharmacologyPharmacy Foundation of Haarlem HospitalsHaarlemThe Netherlands
  2. 2.Department of OtorhinolaryngologySpaarne HospitalHaarlemThe Netherlands

Personalised recommendations